Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Cellectis S.A. - American Depositary Shares
(NQ:
CLLS
)
1.400
UNCHANGED
Delayed Quote
Updated: 4:00 PM EDT, Oct 1, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
685
Open
1.400
Bid (Size)
1.410 (12,200)
Ask (Size)
1.450 (2,000)
Prev. Close
1.400
Today's Range
1.400 - 1.400
52wk Range
1.250 - 5.480
Shares Outstanding
45,484,310
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Cellectis Unveils In Vivo Gene-Editing Plans for Severe Lipid Disorders
↗
October 01, 2026
Cellectis (NASDAQ:CLLS) outlined plans to advance two preclinical in vivo gene-editing candidates for severe forms of dyslipidemia, targeting hypertriglyceridemia and hypercholesterolemia through...
Via
MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. – CLLS
September 29, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Performance
YTD
-70.8%
-70.8%
1 Month
-57.6%
-57.6%
3 Month
-57.6%
-57.6%
6 Month
-58.9%
-58.9%
1 Year
-57.4%
-57.4%
More News
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. – CLLS
September 22, 2026
From
Pomerantz LLP
Via
GlobeNewswire
CLLS Investors Have Opportunity to Join Cellectis S.A. Fraud Investigation with SBS Law
September 19, 2026
From
Schall, Brown & Schwartz LLP
Via
Business Wire
Securities Fraud Investigation Into Cellectis S.A. (CLLS) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
September 17, 2026
From
Glancy Prongay Wolke & Rotter LLP
Via
Business Wire
Cellectis S.A. (CLLS) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
September 17, 2026
From
Law Offices of Howard G. Smith
Via
Business Wire
Securities Fraud Investigation Into Cellectis S.A. (CLLS) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
September 16, 2026
From
The Law Offices of Frank R. Cruz
Via
Business Wire
Cellectis Announces Strategic Transformation To In Vivo Gene Editing Company
September 14, 2026
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis to Host Conference Call and Webcast on September 14 to Provide a Business Update
September 11, 2026
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Announces Participation in Upcoming Investor Conferences
September 01, 2026
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Reports Financial Results for the Second Quarter 2026
August 06, 2026
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis to Report Second Quarter Financial Results on August 6, 2026
July 30, 2026
From
Cellectis Inc.
Via
GlobeNewswire
Prolynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer as It Advances Multi-Program Obesity and Metabolic Disease Portfolio
July 15, 2026
From
ProLynx Inc.
Via
GlobeNewswire
Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026
June 25, 2026
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress
June 11, 2026
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL
June 09, 2026
From
Cellectis Inc.
Via
GlobeNewswire
Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline
↗
May 21, 2026
Via
The Motley Fool
Topics
Intellectual Property
Regulatory Compliance
Why This Fund Added $12 Million to a Biotech Stock That's Now Down 58% in a Year
↗
May 21, 2026
Via
The Motley Fool
Topics
Economy
Regulatory Compliance
Cellectis’ Annual Shareholders General Meeting to be Held on June 25, 2026
May 20, 2026
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis to Present Clinical Data on Lasme-cel and Eti-cel at EHA 2026 Annual Congress
May 12, 2026
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Reports Financial Results for the First Quarter 2026
May 11, 2026
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis to Report First Quarter Financial Results on May 11, 2026
May 04, 2026
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting
April 27, 2026
From
Cellectis Inc.
Via
GlobeNewswire
Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis’ Allogeneic CAR-T Platform
April 13, 2026
From
Cellectis Inc.
Via
GlobeNewswire
Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges
↗
March 22, 2026
Via
The Motley Fool
Frequently Asked Questions
Is Cellectis S.A. - American Depositary Shares publicly traded?
Yes, Cellectis S.A. - American Depositary Shares is publicly traded.
What exchange does Cellectis S.A. - American Depositary Shares trade on?
Cellectis S.A. - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Cellectis S.A. - American Depositary Shares?
The ticker symbol for Cellectis S.A. - American Depositary Shares is CLLS on the Nasdaq Stock Market
What is the current price of Cellectis S.A. - American Depositary Shares?
The current price of Cellectis S.A. - American Depositary Shares is 1.400
When was Cellectis S.A. - American Depositary Shares last traded?
The last trade of Cellectis S.A. - American Depositary Shares was at 10/01/26 04:00 PM ET
What is the market capitalization of Cellectis S.A. - American Depositary Shares?
The market capitalization of Cellectis S.A. - American Depositary Shares is 63.68M
How many shares of Cellectis S.A. - American Depositary Shares are outstanding?
Cellectis S.A. - American Depositary Shares has 64M shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
